The Food and Drug Administration (FDA) approved Khapzory (levoleucovorin) injection, a folate analog for 3 indications.
The Food and Drug Administration (FDA) approved levoleucovorin (Khapzory) for injection for 3 indications.
The agent, which is a chemotherapy protective drug, is approved for the following:
For methotrexate toxicity, levoleucovorin is usually given every 6 hours for 10 doses. For colorectal cancer, the drug is usually given daily as a 5-day treatment, repeated every 4 to 5 weeks.
Common adverse events with levoleucovorin include nausea, vomiting, diarrhea, or mouth sores.
“Khapzory is the first levoleucovorin product approved by the FDA that contains sodium in its formulation,” Joe Turgeon, president and chief executive officer of Spectrum Pharmaceuticals, the agent’s manufacturer, said in a statement. “This (new drug application) submission was part of the lifecycle management of our legacy product, Fusilev.”